Document Detail


Amantadine enhancement of arousal and cognition after traumatic brain injury.
MedLine Citation:
PMID:  18212258     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To determine the role of amantadine therapy for early arousal and improved cognition in traumatic brain injury (TBI). DATA SOURCES: Literature was accessed through MEDLINE (1950-August 2007) using the MeSH terms amantadine, brain injuries, cognition, and arousal. PubMed (through August 2007) terms included amantadine, traumatic brain injury, and cerebral injury. STUDY SELECTION AND DATA EXTRACTION: All studies of amantadine (used <6 mo after injury) for enhancement of arousal or cognition in patients with TBI were reviewed. DATA SYNTHESIS: Many cases of TBI are associated with frontal lobe injury. As a dopamine agonist, amantadine is thought to be involved in frontal lobe stimulation. Two case reports, 3 retrospective studies, and 2 randomized, double-blind, controlled trials of amantadine therapy for early arousal in TBI were identified and reviewed. Limitations of the available studies include open design, retrospective design, and heterogeneous brain injury types. Results have been inconsistent between studies, largely due to variability in designs, heterogeneity in patient populations, time following injury, and use of numerous different outcome measures. Despite these limitations, improvements in arousal and cognition, as documented by the Glasgow Coma Scale and other measures, have been observed in patients with TBI when amantadine has been initiated 3 days to 5 months after injury. CONCLUSIONS: At doses of 200-400 mg/day, amantadine appears to safely improve arousal and cognition in patients with TBI. Additional prospective controlled studies with homogeneous patient populations will better define the role of amantadine for early arousal.
Authors:
Elizabeth Sawyer; Laurie S Mauro; Martin J Ohlinger
Related Documents :
20122578 - Effects of trace element supplementation on the inflammatory response in a rabbit model...
24078528 - Metal ion levels from well-functioning birmingham hip resurfacings decline significantl...
19969148 - Complications of recombinant activated human coagulation factor vii.
23592558 - Cardi-o-fix duct occluder versus amplatzer duct occluder for closure of patent ductus a...
21561348 - Anterior colporrhaphy versus transvaginal mesh for pelvic-organ prolapse.
16100178 - Outcome of coronary artery bypass operations in patients with renal insufficiency with ...
Publication Detail:
Type:  Journal Article; Review     Date:  2008-01-22
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  42     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-04-18     Completed Date:  2008-06-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  247-52     Citation Subset:  IM    
Affiliation:
Parma Community General Hospital, Parma, OH, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amantadine / pharmacology,  therapeutic use*
Arousal / drug effects*,  physiology
Brain Injuries / drug therapy*,  physiopathology,  psychology
Cognition / drug effects*,  physiology
Humans
Recovery of Function / drug effects,  physiology
Time Factors
Chemical
Reg. No./Substance:
768-94-5/Amantadine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment options in imatinib-resistant chronic myelogenous leukemia.
Next Document:  Comparison of the Short-Form Survey 12 and the MacNew Heart Disease Health-Related Quality of Life S...